Kupando - Latest News and Information
Kupando is a Berlin-based biopharmaceutical company focused on developing dual Toll-Like Receptor 4/7 agonists that stimulate innate immunity and induce trained innate immunity. Its lead candidate, KUP101, aims to treat cancer and infectious diseases with a tumor- and pathogen-agnostic approach, potentially enhancing responses when used alone or in combination with other therapies. The company emphasizes first-in-class, small-molecule TLR4/7 agonists with a pipeline spanning oncology and antimicrobial resistance indications. By leveraging host-directed immunomodulation, Kupando seeks to address unmet medical needs in cancer and infectious disease management on a global scale.
No recent news for this company.
